<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455297</url>
  </required_header>
  <id_info>
    <org_study_id>17120</org_study_id>
    <nct_id>NCT02455297</nct_id>
  </id_info>
  <brief_title>Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)</brief_title>
  <official_title>A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess objective response rate (ORR) in patients
      with relapsed or refractory MCL who failed ibrutinib treatment or were unable to tolerate
      ibrutinib.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 24, 2015</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">April 8, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>ORR is defined as the proportion of patients who have a best overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano response criteria in NHL 2014.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the proportion of patients who have a best overall response of CR during study conduct according to the criteria defined by the Lugano response criteria in NHL 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the proportion of patients who have a best response of CR, PR, or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the time (in days) from the date of first administration of study treatment to radiological disease progression or death from any cause (if death occurs before radiological progression is documented). PFS for patients without radiological progression or death at the time of analysis will be censored at the last date of evaluable tumor assessment. PFS for alive patients who have no tumor assessments after baseline will be censored at day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the time (in days) from the date of first observed tumor response of CR or PR, whichever was noted earlier, to radiological disease progression or death from any cause (if death occurs before radiological progression is documented)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the time (in days) from the date of first administration of study treatment to death from any cause. The OS time for patients alive at the time of analysis will be censored at their last known alive date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events (TEAEs) as a measure of safety and tolerability</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Lymphoma, Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>Copanlisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Copanlisib (BAY80-6946) solution for IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (BAY80-6946)</intervention_name>
    <description>Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.</description>
    <arm_group_label>Copanlisib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed MCL

          -  Patients who have previously received treatment with ibrutinib (modified by amendment
             1), including:

               -  Completion of at least 1 cycle of treatment with ibrutinib and confirmed evidence
                  of disease progression or refractoriness to treatment or

               -  Discontinuation of ibrutinib treatment at an earlier time due to toxicity

          -  Measurable disease according to the Lugano Classification

          -  At least 28 days or 5 half-lives, whichever is shorter, from the completion of
             anti-cancer treatment (including, but not limited to, immunotherapy, chemotherapy,
             targeted therapy and biologic therapy) to the start of study treatment, excluding
             ibrutinib where the window may be less and at minimum 3 days (modified by amendment 1)

          -  Availability of fresh tumor tissue at screening

          -  Male or female patients ≥ 18 years old

          -  ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2

          -  Left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated
             acquisition (MUGA) scan ≥ the lower limit of normal (LLN) for the Institution

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Any of the following as the only site(s) of disease: palpable lymph nodes not visible
             on imaging studies, skin lesions, or bone marrow involvement only

          -  Current central nervous system (CNS) involvement by lymphoma

          -  New York Heart Association (NYHA) class III or IV heart disease

          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
             months). Myocardial infarction less than 6 months before start of study treatment

          -  Uncontrolled arterial hypertension despite optimal medical management (per
             investigator's assessment) (modified by amendment 1)

          -  Type I or II diabetes mellitus with HbA1c &gt; 8.5% at screening (modified by amendment
             1)

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 3 months before start of study treatment. However, if a patient has recovered
             to ECOG performance status of ≤ 2 he/she may be enrolled provided that other
             eligibility criteria are met

          -  Ongoing or active infection of Common Terminology Criteria for Adverse Events (CTCAE)
             Grade ≥ 3

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Acute or chronic hepatitis B (HBV) or hepatitis C (HCV) infection requiring
             concomitant treatment prohibited by this protocol (i.e.immunosuppressive therapy)

          -  History or concurrent condition of interstitial lung disease of any severity and/or
             severely impaired lung function (as judged by the investigator)

          -  Prior treatment with PI3K inhibitor(s)

          -  Cytomegalovirus (CMV) PCR positive at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

